<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01395901</url>
  </required_header>
  <id_info>
    <org_study_id>PALO-10-14</org_study_id>
    <nct_id>NCT01395901</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients</brief_title>
  <official_title>A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinn Healthcare SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of a single palonosetron IV
      dose compared to a single ondansetron IV dose in the prevention of postoperative nausea and
      vomiting through 24 hours after surgery in children aged from neonates up to less than 17
      years undergoing elective surgical procedures requiring general intravenous anesthesia. The
      secondary objective is to evaluate the safety and tolerability of IV palonosetron in
      pediatric patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With Complete Response</measure>
    <time_frame>0-24 hours after T0</time_frame>
    <description>Complete Response was defined as no vomiting, no retching, and no use of antiemetic rescue medication during the first 24 hours postoperatively, starting at T0. Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With no Vomiting</measure>
    <time_frame>0-24 hours after T0</time_frame>
    <description>Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Without Emetic Episodes</measure>
    <time_frame>0-24 hours after T0</time_frame>
    <description>An emetic episode was defined as one or more continuous vomits (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Without Antiemetic Rescue Medication</measure>
    <time_frame>0-24 hours after T0</time_frame>
    <description>Rescue medications are any medications with potential antiemetic effect taken in the 24 hours after patient wake-up from anaesthesia (T0).Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Without Nausea (Patient Aged &gt; 6 Years)</measure>
    <time_frame>0-24 hours after T0</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">670</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Palonosetron and placebo to Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: Palonosetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron and placebo to Palonosetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: Comparator: Ondansetron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)</description>
    <arm_group_label>Palonosetron and placebo to Ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Single dose Ondansetron IV:
0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for &gt;40 kg;
13 years to less than 17 years dose: 4 mg</description>
    <arm_group_label>Ondansetron and placebo to Palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ondansetron</intervention_name>
    <arm_group_label>Palonosetron and placebo to Ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Palonosetron</intervention_name>
    <arm_group_label>Ondansetron and placebo to Palonosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient aged from full term neonate to less than 17 years.

          -  In-patient or out-patient scheduled to undergo one of the following procedures:

               -  ear, nose and throat surgery (e.g., tonsillectomy, adenoidectomy, myringotomy),

               -  eye surgery (e.g. strabismus, vitreoretinal, cataract surgery),

               -  urological surgery (e.g. orchidopexy, varicocoele),

               -  plastic reconstructive surgery (e.g. cleft lip/cleft palate, burn procedures
                  involving the scalp),

               -  hernia repair,

               -  orthopedic surgery (e.g. foot and ankle deformities, arthroscopic surgeries, ACL
                  surgery),.

               -  cardiac surgery,

               -  neurosurgery.

          -  Patient is scheduled to undergo surgery requiring general intravenous anesthesia

          -  Patient is scheduled to receive nitrous oxide during the maintenance phase of
             anesthesia

          -  Patient weighs at least 3.2 kg

          -  ASA physical status I, II or III

          -  Fertile patients (male or female) must use reliable contraceptive measures

          -  Female patients who have attained menarche must have a negative pregnancy test at the
             screening visit (Visit 1) and at study treatment visit (Visit 2)

          -  For patients with known hepatic impairment: in the Investigator's opinion, the
             impairment does not jeopardize the patient's safety during the study

          -  For patients with known renal impairment: in the Investigator's opinion, the
             impairment does not jeopardize the patient's safety during the study

        Exclusion Criteria:

          -  Lactating females

          -  Patient aged ≤6 years who received any investigational drug within 90 days prior to
             Day 1, or patient aged &gt;6 years who received any investigational drug within 30 days
             prior to Day 1 or is expected to receive investigational drugs prior to study
             completion.

          -  Patient having participated in any previous trial with palonosetron.

          -  History of allergy to any components or any other contraindications to the use of any
             5-HT3 receptor antagonists

          -  Patient to undergo emergency surgery

          -  Patient scheduled to receive regional anesthesia (lumbar, epidural, spinal) alone or
             in conjunction with general intravenous anesthesia

          -  Patient scheduled to receive laryngeal mask anesthesia

          -  Patient scheduled to receive propofol during the maintenance phase of anesthesia

          -  Patient suffering from any concomitant disease uncontrolled by therapy, which, in the
             judgment of the Investigator, could compromise the outcome of surgery

          -  Patient with history of gastro-esophageal reflux (except for patients up to 12 months)

          -  Patient with ongoing vomiting from any organic cause

          -  Patient having experienced any vomiting, retching, or nausea within 24 hours prior to
             the administration of the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shoals Clinical Research Associates</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shoals Medical Research, LLC</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute - University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRC of Jackson</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina Hospitals</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Developers</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Orthopedic Specialist, P.A</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <zip>76051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEMIC, Otorhinolaryngology Department</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Medico Rio Cuarto</name>
      <address>
        <city>Rio Cuarto</city>
        <zip>X5800AEV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno - Children's Medical Centre</name>
      <address>
        <city>Brno</city>
        <zip>61300</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Pilsen- Paediatric Clinic</name>
      <address>
        <city>Plzen-Lochotin</city>
        <zip>30460</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Praha</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Znojmo, State-Funded Organisation, Department of Pediatrics</name>
      <address>
        <city>Znojmo</city>
        <zip>669 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmeleis University</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Istvan and St Laszlo Corporate Hospital; Paediatric Intensive Care Unit</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Municipal Council's St Janos Hospital and North Buda United Hospitals; Central Anaesthesiology and Intensive Care Unit</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Panthaleon Hospital; Central Department of Anaesthesiology and Intensive Care Unit</name>
      <address>
        <city>Dunaújváros</city>
        <zip>2400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pandy Kalman County Hospital; Department of Central Anaesthesiology and Intensive Care Unit</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Surgery and Urology of Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Anesthesiology and Intensive Care</name>
      <address>
        <city>Lodz</city>
        <zip>91-738</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Anesthesiology and Intensive Care</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care and Anesthesiology</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Surgery</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-369</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Pediatric Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>PR 00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution Arkhangelsk Regional Children's Hospital</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>132002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution: St. Petersburg Research Institute of Ear, Throat, Nose and Speech under the MoH Care and Social Development of the Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinic MEDEM</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Pediatric Medical Academy</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Region State Healthcare Institution</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150042</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk Regional Childrens Clinical Hospital</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Childrens Clinical Hospital</name>
      <address>
        <city>Donetsk</city>
        <zip>83052</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Childrens Clinical Hospital</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital n#30</name>
      <address>
        <city>Kharkiv</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research and Development Center for Prophylactic and Clinical Medicine</name>
      <address>
        <city>Kyiv</city>
        <zip>01133</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Specialized Childrens Hospital OKHMATDYT</name>
      <address>
        <city>Kyiv</city>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.P. Filatov Institute of Eye Diseases and Tissue Therapy</name>
      <address>
        <city>Odesa</city>
        <zip>65061</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporizhia Regional Clinical Childrens Hospital</name>
      <address>
        <city>Zaporizhia</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2011</study_first_submitted>
  <study_first_submitted_qc>July 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2011</study_first_posted>
  <results_first_submitted>June 27, 2014</results_first_submitted>
  <results_first_submitted_qc>July 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2014</results_first_posted>
  <disposition_first_submitted>March 28, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 28, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 4, 2013</disposition_first_posted>
  <last_update_submitted>July 29, 2014</last_update_submitted>
  <last_update_submitted_qc>July 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of Postoperative Nausea and Vomiting</keyword>
  <keyword>Palonosetron</keyword>
  <keyword>Ondansetron</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 44 sites were initiated in seven countries with 12, 9, 5, 5, 5, 6 and 2 investigative sites in the United States, Ukraine, Hungary, Poland, Russia, Czech Republic and Argentina. Patients were enrolled into the study by 39 out of 44 Investigators enrolling at least one patient.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Palonosetron and Placebo to Ondansetron</title>
          <description>Intervention: Drug: Palonosetron
Palonosetron: Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
Placebo to Ondansetron</description>
        </group>
        <group group_id="P2">
          <title>Ondansetron and Placebo to Palonosetron</title>
          <description>Intervention: Drug: Comparator: Ondansetron
Ondansetron: Single dose Ondansetron IV:
0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for &gt;40 kg;
13 years to less than 17 years dose: 4 mg
Placebo to Palonosetron</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="336">Randomized Population</participants>
                <participants group_id="P2" count="334">Randomized Population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="326">Treated patients completing the study</participants>
                <participants group_id="P2" count="329">Treated patients completing the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not received study drug</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set Population</population>
      <group_list>
        <group group_id="B1">
          <title>Palonosetron and Placebo to Ondansetron</title>
          <description>Intervention: Drug: Palonosetron
Palonosetron: Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
Placebo to Ondansetron</description>
        </group>
        <group group_id="B2">
          <title>Ondansetron and Placebo to Palonosetron</title>
          <description>Intervention: Drug: Comparator: Ondansetron
Ondansetron: Single dose Ondansetron IV:
0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for &gt;40 kg;
13 years to less than 17 years dose: 4 mg
Placebo to Palonosetron</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="331"/>
            <count group_id="B2" value="330"/>
            <count group_id="B3" value="661"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 &lt;6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 &lt;12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 &lt;17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="307"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With Complete Response</title>
        <description>Complete Response was defined as no vomiting, no retching, and no use of antiemetic rescue medication during the first 24 hours postoperatively, starting at T0. Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
        <time_frame>0-24 hours after T0</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized patients who received the active study drug, general anesthesia and surgery (evaluable patients). Following the intent-to-treat principle, patients were assigned to the study treatment arm according to their randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron and Placebo to Ondansetron</title>
            <description>Intervention: Drug: Palonosetron
Palonosetron: Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
Placebo to Ondansetron</description>
          </group>
          <group group_id="O2">
            <title>Ondansetron and Placebo to Palonosetron</title>
            <description>Intervention: Drug: Comparator: Ondansetron
Ondansetron: Single dose Ondansetron IV:
0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for &gt;40 kg;
13 years to less than 17 years dose: 4 mg
Placebo to Palonosetron</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Complete Response</title>
          <description>Complete Response was defined as no vomiting, no retching, and no use of antiemetic rescue medication during the first 24 hours postoperatively, starting at T0. Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
          <population>The Full Analysis Set (FAS) included all randomized patients who received the active study drug, general anesthesia and surgery (evaluable patients). Following the intent-to-treat principle, patients were assigned to the study treatment arm according to their randomized treatment.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="331"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" lower_limit="73.3" upper_limit="82.5"/>
                    <measurement group_id="O2" value="82.7" lower_limit="78.1" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis (H0) was stated as:
• H0 : CR 0-24 hr palonosetron - CR 0-24 hr ondansetron &lt;-10%
The alternative hypothesis (H1) was stated as:
• H1 : CR 0-24 hr palonosetron - CR 0-24 hr ondansetron &gt;-10%
A power of 80% was used for sample size computation.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For the primary efficacy analysis, the confidence interval (CI) was built on the FAS using the stratum adjusted Mantel-Haenszel (MH) method with correction of continuity. The non-inferiority margin was -10%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With no Vomiting</title>
        <description>Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
        <time_frame>0-24 hours after T0</time_frame>
        <population>The Full Analysis Set (FAS) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron and Placebo to Ondansetron</title>
            <description>Intervention: Drug: Palonosetron
Palonosetron: Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
Placebo to Ondansetron</description>
          </group>
          <group group_id="O2">
            <title>Ondansetron and Placebo to Palonosetron</title>
            <description>Intervention: Drug: Comparator: Ondansetron
Ondansetron: Single dose Ondansetron IV:
0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for &gt;40 kg;
13 years to less than 17 years dose: 4 mg
Placebo to Palonosetron</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With no Vomiting</title>
          <description>Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
          <population>The Full Analysis Set (FAS) population.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="331"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" lower_limit="78.5" upper_limit="86.9"/>
                    <measurement group_id="O2" value="87.6" lower_limit="83.4" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Without Emetic Episodes</title>
        <description>An emetic episode was defined as one or more continuous vomits (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
        <time_frame>0-24 hours after T0</time_frame>
        <population>The Full Analysis Set (FAS) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron and Placebo to Ondansetron</title>
            <description>Intervention: Drug: Palonosetron
Palonosetron: Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
Placebo to Ondansetron</description>
          </group>
          <group group_id="O2">
            <title>Ondansetron and Placebo to Palonosetron</title>
            <description>Intervention: Drug: Comparator: Ondansetron
Ondansetron: Single dose Ondansetron IV:
0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for &gt;40 kg;
13 years to less than 17 years dose: 4 mg
Placebo to Palonosetron</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Without Emetic Episodes</title>
          <description>An emetic episode was defined as one or more continuous vomits (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
          <population>The Full Analysis Set (FAS) population.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="331"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1" lower_limit="75.3" upper_limit="84.1"/>
                    <measurement group_id="O2" value="83.9" lower_limit="79.4" upper_limit="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Without Antiemetic Rescue Medication</title>
        <description>Rescue medications are any medications with potential antiemetic effect taken in the 24 hours after patient wake-up from anaesthesia (T0).Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
        <time_frame>0-24 hours after T0</time_frame>
        <population>The Full Analysis Set (FAS) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron and Placebo to Ondansetron</title>
            <description>Intervention: Drug: Palonosetron
Palonosetron: Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
Placebo to Ondansetron</description>
          </group>
          <group group_id="O2">
            <title>Ondansetron and Placebo to Palonosetron</title>
            <description>Intervention: Drug: Comparator: Ondansetron
Ondansetron: Single dose Ondansetron IV:
0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for &gt;40 kg;
13 years to less than 17 years dose: 4 mg
Placebo to Palonosetron</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Without Antiemetic Rescue Medication</title>
          <description>Rescue medications are any medications with potential antiemetic effect taken in the 24 hours after patient wake-up from anaesthesia (T0).Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.</description>
          <population>The Full Analysis Set (FAS) population.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="331"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="89.6" upper_limit="95.4"/>
                    <measurement group_id="O2" value="96.4" lower_limit="93.6" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Without Nausea (Patient Aged &gt; 6 Years)</title>
        <time_frame>0-24 hours after T0</time_frame>
        <population>The Full Analysis Set (FAS) population aged ≥ 6 years</population>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron and Placebo to Ondansetron</title>
            <description>Intervention: Drug: Palonosetron
Palonosetron: Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
Placebo to Ondansetron</description>
          </group>
          <group group_id="O2">
            <title>Ondansetron and Placebo to Palonosetron</title>
            <description>Intervention: Drug: Comparator: Ondansetron
Ondansetron: Single dose Ondansetron IV:
0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for &gt;40 kg;
13 years to less than 17 years dose: 4 mg
Placebo to Palonosetron</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Without Nausea (Patient Aged &gt; 6 Years)</title>
          <population>The Full Analysis Set (FAS) population aged ≥ 6 years</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.2" lower_limit="76.9" upper_limit="88.2"/>
                    <measurement group_id="O2" value="82.0" lower_limit="75.5" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Palonosetron and Placebo to Ondansetron</title>
          <description>Intervention: Drug: Palonosetron
Palonosetron: Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
Placebo to Ondansetron</description>
        </group>
        <group group_id="E2">
          <title>Ondansetron and Placebo to Palonosetron</title>
          <description>Intervention: Drug: Comparator: Ondansetron
Ondansetron: Single dose Ondansetron IV:
0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for &gt;40 kg;
13 years to less than 17 years dose: 4 mg
Placebo to Palonosetron</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Meddra 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Palatal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Ureteric anastomosis complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Glioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="234" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="331"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="331"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="331"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="331"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="149" subjects_affected="147" subjects_at_risk="331"/>
                <counts group_id="E2" events="126" subjects_affected="123" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="331"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="331"/>
                <counts group_id="E2" events="39" subjects_affected="37" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="331"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="331"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If Sponsor does not submit a publication regarding the study to a journal within 12 months from study data analysis completion, the Investigator may publish an analysis of the study data collected as a result of the conduct of the study by the Investigator. The Investigator shall ensure that at least 60 days prior to submitting/presenting a manuscript/material relating to study to publishers a copy of all manuscripts/materials is provided to the Sponsor to allow the Sponsor sixty days to review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Salvatore Chessari</name_or_title>
      <organization>Helsinn Healthcare SA</organization>
      <phone>+41 91 985 21 21</phone>
      <email>salvatore.chessari@helsinn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

